Isolation and detection of circulating tumour cells from metastatic melanoma patients using a slanted spiral microfluidic device

Circulating Tumour Cells (CTCs) are promising cancer biomarkers. Several methods have been developed to isolate CTCs from blood samples. However, the isolation of melanoma CTCs is very challenging as a result of their extraordinary heterogeneity, which has hindered their biological and clinical study. Thus, methods that isolate CTCs based on their physical properties, rather than surface marker expression, such as microfluidic devices, are greatly needed in melanoma. Here, we assessed the ability of the slanted spiral microfluidic device to isolate melanoma CTCs via label-free enrichment. We demonstrated that this device yields recovery rates of spiked melanoma cells of over 80% and 55%, after one or two rounds of enrichment, respectively. Concurrently, a two to three log reduction of white blood cells was achieved with one or two rounds of enrichment, respectively. We characterised the isolated CTCs using multimarker flow cytometry, immunocytochemistry and gene expression. The results demonstrated that CTCs from metastatic melanoma patients were highly heterogeneous and commonly expressed stem-like markers such as PAX3 and ABCB5. The implementation of the slanted microfluidic device for melanoma CTC isolation enables further understanding of the biology of melanoma metastasis for biomarker development and to inform future treatment approaches.

[1]  Jongyoon Han,et al.  Ultra-fast, label-free isolation of circulating tumor cells from blood using spiral microfluidics , 2015, Nature Protocols.

[2]  M. Ziman,et al.  PAX3 Expression in Normal Skin Melanocytes and Melanocytic Lesions (Naevi and Melanomas) , 2010, PloS one.

[3]  Rika Deraemaecker,et al.  Expression of MAGE genes in primary and metastatic cutaneous melanoma , 1995, International journal of cancer.

[4]  J. Mesirov,et al.  GenePattern 2.0 , 2006, Nature Genetics.

[5]  T. Luger,et al.  RANK is expressed in metastatic melanoma and highly upregulated on melanoma-initiating cells. , 2011, The Journal of investigative dermatology.

[6]  Sridhar Ramaswamy,et al.  RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance , 2015, Science.

[7]  J. Blake,et al.  Pax3 transcripts in melanoblast development , 2005, Development, growth & differentiation.

[8]  Eugene J. Lim,et al.  Microfluidic, marker-free isolation of circulating tumor cells from blood samples , 2014, Nature Protocols.

[9]  Mohamed H. Sayegh,et al.  Identification of cells initiating human melanomas , 2008, Nature.

[10]  Bo Lu,et al.  3D microfilter device for viable circulating tumor cell (CTC) enrichment from blood , 2011, Biomedical microdevices.

[11]  M. Ziman,et al.  PAX3 across the spectrum: from melanoblast to melanoma , 2009, Critical reviews in biochemistry and molecular biology.

[12]  N. Dhomen,et al.  Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma. , 2016, Cancer discovery.

[13]  John Hines,et al.  Optimization and Evaluation of a Novel Size Based Circulating Tumor Cell Isolation System , 2015, PloS one.

[14]  Sumitra Mohan,et al.  Clinical evaluation of a novel microfluidic device for epitope-independent enrichment of circulating tumour cells in patients with small cell lung cancer. , 2016, The Analyst.

[15]  G. Boyle,et al.  Mechanisms Contributing to Differential Regulation of PAX3 Downstream Target Genes in Normal Human Epidermal Melanocytes versus Melanoma Cells , 2015, PloS one.

[16]  C. Ni,et al.  Prognostic value of circulating tumor cells in metastatic breast cancer: a systemic review and meta-analysis , 2016, Clinical and Translational Oncology.

[17]  K. O'Byrne,et al.  Short term ex-vivo expansion of circulating head and neck tumour cells , 2016, Oncotarget.

[18]  A. Giblin,et al.  Incidence, mortality and survival in cutaneous melanoma. , 2007, Journal of plastic, reconstructive & aesthetic surgery : JPRAS.

[19]  James B. Freeman,et al.  Evaluation of a multi-marker immunomagnetic enrichment assay for the quantification of circulating melanoma cells , 2012, Journal of Translational Medicine.

[20]  K. Flaherty,et al.  Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression. , 2015, European journal of cancer.

[21]  M. Gore,et al.  Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Q. Zhan,et al.  ABCB5 maintains melanoma-initiating cells through a proinflammatory cytokine signaling circuit. , 2014, Cancer research.

[23]  Anil K Sood,et al.  A novel platform for detection of CK+ and CK- CTCs. , 2011, Cancer discovery.

[24]  Jongyoon Han,et al.  An ultra-high-throughput spiral microfluidic biochip for the enrichment of circulating tumor cells. , 2014, The Analyst.

[25]  Sridhar Ramaswamy,et al.  Isolation and molecular characterization of circulating melanoma cells. , 2014, Cell reports.

[26]  M. Millward,et al.  Markers of circulating tumour cells in the peripheral blood of patients with melanoma correlate with disease recurrence and progression , 2013, The British journal of dermatology.

[27]  H. Rizos,et al.  Differential PAX3 functions in normal skin melanocytes and melanoma cells. , 2011, Biochemical and biophysical research communications.

[28]  Alison Stopeck,et al.  Circulating tumor cells, disease progression, and survival in metastatic breast cancer. , 2004, The New England journal of medicine.

[29]  Jedd D. Wolchok,et al.  Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. , 2016 .

[30]  Mehmet Toner,et al.  Inertial Focusing for Tumor Antigen–Dependent and –Independent Sorting of Rare Circulating Tumor Cells , 2013, Science Translational Medicine.

[31]  Daniela Massi,et al.  Application of a filtration- and isolation-by-size technique for the detection of circulating tumor cells in cutaneous melanoma. , 2010, The Journal of investigative dermatology.

[32]  Tuan Zea Tan,et al.  Short-term expansion of breast circulating cancer cells predicts response to anti-cancer therapy , 2015, Oncotarget.

[33]  P. Lorigan,et al.  Biomarker utility of circulating tumor cells in metastatic cutaneous melanoma. , 2013, The Journal of investigative dermatology.

[34]  Ali Asgar S. Bhagat,et al.  Clinical Validation of an Ultra High-Throughput Spiral Microfluidics for the Detection and Enrichment of Viable Circulating Tumor Cells , 2014, PloS one.

[35]  Tanja Fehm,et al.  Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer , 2016, Clinical Cancer Research.

[36]  K. Isselbacher,et al.  Isolation of circulating tumor cells using a microvortex-generating herringbone-chip , 2010, Proceedings of the National Academy of Sciences.

[37]  D. Schadendorf,et al.  Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  K. Flaherty,et al.  Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy , 2016, Cancer cell.

[39]  James B. Freeman,et al.  Monitoring changes in circulating tumour cells as a prognostic indicator of overall survival and treatment response in patients with metastatic melanoma , 2014, BMC Cancer.

[40]  Jeffrey E Gershenwald,et al.  Final version of 2009 AJCC melanoma staging and classification. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  T. Schlomm,et al.  Improved detection of circulating tumor cells in non-metastatic high-risk prostate cancer patients , 2016, Scientific Reports.

[42]  D. Schadendorf,et al.  Genomic analysis and 3-y efficacy and safety update of COMBI-d: A phase 3 study of dabrafenib (D) + trametinib (T) vs D monotherapy in patients (pts) with unresectable or metastatic BRAF V600E/K-mutant cutaneous melanoma. , 2016 .

[43]  C. Shea,et al.  PAX3 expression in primary melanomas and nevi , 2008, Modern Pathology.

[44]  Sridhar Ramaswamy,et al.  A microfluidic device for label-free, physical capture of circulating tumor cell-clusters , 2015, Nature Methods.

[45]  P. Lorigan,et al.  Prevalence and heterogeneity of circulating tumour cells in metastatic cutaneous melanoma , 2014, Melanoma research.

[46]  Peter C. Y. Chen,et al.  Slanted spiral microfluidics for the ultra-fast, label-free isolation of circulating tumor cells. , 2014, Lab on a chip.

[47]  J. Wenner,et al.  Cytokeratin 20 improves the detection of circulating tumor cells in patients with colorectal cancer. , 2015, Cancer letters.

[48]  J. Annereau,et al.  Melanoma Chemotherapy Leads to the Selection of ABCB5-Expressing Cells , 2012, PloS one.

[49]  Li Wang,et al.  Microfluidic device with integrated microfilter of conical-shaped holes for high efficiency and high purity capture of circulating tumor cells , 2014, Scientific Reports.

[50]  Melanie Ziman,et al.  Detection of BRAF-V600E and V600K in melanoma circulating tumour cells by droplet digital PCR. , 2015, Clinical biochemistry.

[51]  T. Wobbes,et al.  Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions. , 1997, Cancer research.

[52]  M. Millward,et al.  Circulating Melanoma Cell Subpopulations: Their Heterogeneity and Differential Responses to Treatment , 2015, The Journal of investigative dermatology.

[53]  J. Epstein,et al.  Pax3 functions at a nodal point in melanocyte stem cell differentiation , 2005, Nature.

[54]  K. Pantel,et al.  Challenges in circulating tumour cell research , 2014, Nature Reviews Cancer.

[55]  Sridhar Ramaswamy,et al.  Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility , 2014, Science.